CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)

Launched by CENTRO MEDICO TEKNON · Oct 18, 2020

Keywords

ClinConnect Summary

The DEVELOP-VT trial is studying how to predict the risk of serious heart rhythm problems, called ventricular tachycardia (VT), in patients who have healed from a heart attack. Researchers are particularly interested in a specific type of heart tissue called "border zone channel" (BZC) mass, which can be measured using a special imaging technique called cardiac magnetic resonance imaging (CMR). This trial aims to see if measuring the BZC mass can help identify patients at higher risk of developing VT, helping doctors make better decisions about treatments like implantable cardioverter-defibrillators (ICDs), which can prevent sudden cardiac death.

To participate in this study, you must be over 18 years old and have stable heart disease that has lasted for more than three months after a heart attack. You should also be expected to live for at least another year and be in good health. During the trial, participants will undergo CMR scans to measure their heart tissue and will be monitored for any VT events over time. It’s important to note that individuals with certain heart conditions, those who are pregnant, or those with a very short life expectancy may not be eligible to join. This study is currently recruiting participants, and it offers a chance to contribute to understanding and improving heart health for people with a history of heart attacks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years.
• • Chronic (\> 3 months after the index coronary event), stable ischemic heart disease, irrespectively of the LVEF.
• • Life expectancy of \> 1 year with a good functional status.
• • Signed informed consent.
• Exclusion Criteria:
• • Age \< 18 years.
• • Pregnancy.
• • Life expectancy of \< 1 year, or bad functional status (NYHA IV functional class).
• • Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)
• • Previously documented sustained ventricular arrhythmias.
• • Impossibility or contraindications to undergo a contrast-enhanced CMR study.
• • Concomitant investigation treatments.
• • Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.